Sartorius Establishes Scientific Advisory Board

Article

The new scientific advisory board will oversee innovation projects, identify and develop key new technologies, and be responsible for forming high-caliber alliances with innovative start-ups.

On Dec. 28, 2019, Sartorius announced that it has established a scientific advisory board for its corporate research activities, which will oversee overarching innovation projects. The scientific advisory board will be tasked with identifying and developing key technologies and application fields of the future and establishing a number of high-caliber alliances with start-up companies as well as other partners who contribute to innovation in the life science sectors.

“The unbiased advice of the [s]cientific [a]dvisory [b]oard will support Sartorius in maintaining a diverse, external view of trends in the industry and in guiding Sartorius' technological initiatives,” said Executive Board Chairman and CEO Dr. Joachim Kreuzburg, in a company press release.

“The members of the [s]cientific [a]dvisory [b]oard are leading experts in a diverse range of life science areas, including cell therapy processing, cell line engineering, stem cells, cell analytics, and biosensors. We are delighted to have such a strong group of individuals join our [board],” added Professor Oscar-Werner Reif, PhD, Sartorius’ chief technology officer and head of corporate research, in the press release.

The members of Sartorius’ scientific advisory board include:

  • Michael J. Betenbaugh, professor of Chemical and Biomolecular Engineering. Betenbaugh is chairman of the Department of Chemical and Biomolecular Engineering at Johns Hopkins University, Baltimore, MD. His focus is on cell line engineering, cell media and mammalian cell development, omics simulation and modeling, and glyco-engineering. He is a company founder and a member of several academic and industrial boards.

  • Shana O. Kelley, professor at the University of Toronto and a member of the departments of Chemistry, Biochemistry, Pharmaceutical Sciences, and Biomedical Engineering. The Kelley research group works in a variety of areas spanning biophysical and bioanalytical chemistry, chemical biology, and nanotechnology. The group has pioneered new methods for tracking molecular and cellular analytes with unprecedented sensitivity. Kelley is a founder of various start-ups and a member of several academic and industrial boards. Her focus is on biosensors, single-cell profiling, intracellular signaling, and bio-nanomaterials.

  • Christine Mummery, professor and head of the Department of Anatomy and Embryology at the Leiden University Medical Center, Netherlands. Mummery specializes in developmental biology, anatomy, and embryology and conducts primary research, which currently focuses on the development and use of stem cells in cardiovascular development and disease models. She is an elected member of the Royal Netherlands Academy of Sciences, an elected member of the Academia Europea, and an editorial board member of journals that include Stem Cell Research.

  • Yoav Shechtman, assistant professor at the Department of Biomedical Engineering and Lokey Interdisciplinary Center for Life Sciences & Engineering at the Technion Israel Institute of Technology, Israel. Shechtman is a computer scientist and physicist whose main research interests includes localization microscopy, single-particle tracking, super-resolution microscopy, three-dimensional imaging, and single-molecule measurements.

  • Nigel Titchener-Hooker, professor of Biochemical Engineering. Titchener-Hooker is dean of Engineering at the University College London, UK, and is an elected member of the UCL Provost selection panel and editor-in-chief of the journal, Food and Bioproducts Processing. Since 2018, he has been a member of the British Standards Institute committee and was also the past lead of the program of the UCL Innovative Manufacturing Research Centre (IMRC) in Bioprocessing. A focus of his work is on the creation of whole bioprocess models and how to use them to gain process insights and understanding.

Source: Sartorius

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.